Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
Connectyx Technologies Holdings Group, Inc. provides products in the healthcare ma...
Connectyx Technologies Holdings Group, Inc. pro...
Castle Biosciences is a skin cancer diagnostics company focused on providing physi...
Castle Biosciences is a skin cancer diagnostics...
Tricida, Inc. , Tricida, Inc. , is a pharmaceutical company focused on the develop...
Tricida, Inc. , Tricida, Inc. , is a pharmaceut...
Seattle-based Atossa Genetics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical...
Seattle-based Atossa Genetics (NASDAQ: ATOS) is...
Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, AIM:TILS) clinical stage biot...
Tiziana Life Sciences is a dual-listed (NASDAQ:...
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inha...
Pulmatrix is a clinical stage biopharmaceutical...
Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused o...
Mirum Pharmaceuticals Inc. is a clinical-stage ...
Join the National Investor Network and get the latest information with your interests in mind.